Published mark

OMEROS CORP

NASDAQ: OMER. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:262be438-8168-4cf8-8daf-199d474cff1d
SEC CIK
0001285819
Record version
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 18, 2026
Newest evidence
Mar 31, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Giovanni Caforio, M.D.Since Mar 31, 2026
Chair
Not published
Independent
Not published
Published claims
152 distinct sources
Evidence records
120 pinned
Source conflicts
0None open

Built from 2 distinct sources and 12 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

Andreas Grauer, M.D. executive of OMEROS CORP, effective 2026-03-31.

EffectiveEffective Mar 31, 2026E2

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Vice President, Chief Medical OfficerAndreas Grauer, M.D.Mar 2026currentSource reportedE2
Vice President, Regulatory Affairs Quality Systems and Chief Regulatory OfficerCatherine A. Melfi, Ph.D.Mar 2026currentSource reportedE3
Vice President, Finance, Chief Accounting Officer and TreasurerDavid J. BorgesMar 2026currentSource reportedE4
Vice President, Chief Business Development OfficerDavid W. GhesquiereMar 2026currentSource reportedE5
Vice President, Science and Chief Scientific OfficerGeorge Mclean Milne Jr., Ph.D.Mar 2026currentSource reportedE6
President, Chief Executive Officer and Chairman of the Board of DirectorsGiovanni Caforio, M.D.Mar 2026currentSource reportedE7
Vice President, Clinical DevelopmentJ. Steven Whitaker, M.D., J.D.Mar 2026currentSource reportedE8
Vice President, Chemistry, Manufacturing and ControlsMariana N. Dimitrova, Ph.D.Mar 2026currentSource reportedE9
Vice President, Chief Commercial OfficerNadia DacMar 2026currentSource reportedE10
Vice President, Human ResourcesPaul S. WilliamsMar 2026currentSource reportedE11
Vice President, General Counsel and SecretaryPeter B. Cancelmo, J.D.Mar 2026currentSource reportedE12

Board of directors

Evidence
DirectorStatusSinceCommittees

Committees and risk ownership

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerGiovanni Caforio, M.D., President, Chief Executive Officer and Chairman of the Board of Directors, from Mar 31, 2026
Source reportedE7
company:262be438-8168-4cf8-8daf-199d474cff1d:leadership_role:10
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingOMER (NASDAQ)
Source reportedE1
company:262be438-8168-4cf8-8daf-199d474cff1d:security_listing:16
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 18, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameOMEROS CORP
Source reportedE1
company:262be438-8168-4cf8-8daf-199d474cff1d:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:262be438-8168-4cf8-8daf-199d474cff1d:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • BoardNot reviewed. Board composition is the primary accountability structure.
  • CommitteesNot reviewed. Committee mandates show where oversight is delegated.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
12 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 18, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  6. E6
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  7. E7
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  8. E8
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  9. E9
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  10. E10
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  11. E11
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  12. E12
    OMER 10-K executive officers
    sec filing. Published Mar 31, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 18, 2026
  • Andreas Grauer, M.D. executive of OMEROS CORP, effective 2026-03-31.
  • Catherine A. Melfi, Ph.D. executive of OMEROS CORP, effective 2026-03-31.
  • David J. Borges executive of OMEROS CORP, effective 2026-03-31.
  • David W. Ghesquiere executive of OMEROS CORP, effective 2026-03-31.
  • George Mclean Milne Jr., Ph.D. executive of OMEROS CORP, effective 2026-03-31.
  • Giovanni Caforio, M.D. executive of OMEROS CORP, effective 2026-03-31.
  • J. Steven Whitaker, M.D., J.D. executive of OMEROS CORP, effective 2026-03-31.
  • Mariana N. Dimitrova, Ph.D. executive of OMEROS CORP, effective 2026-03-31.
  • Nadia Dac executive of OMEROS CORP, effective 2026-03-31.
  • Paul S. Williams executive of OMEROS CORP, effective 2026-03-31.
  • Peter B. Cancelmo, J.D. executive of OMEROS CORP, effective 2026-03-31.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:262be438-8168-4cf8-8daf-199d474cff1d, version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/omeros-corp

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership11
  4. Board1
  5. Committees0
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps19
  16. Linked people11
  17. Subject and corrections6
  18. Evidence12
  19. Version historyvpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:262be438-8168-4cf8-8daf-199d474cff1d
  • Cite this recordOMEROS CORP
  • Copy canonical URLregistry.alpha.ac/companies/omeros-corp
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    OMEROS CORPCompany
  • Andreas Grauer, M.D.Person
  • Catherine A. Melfi, Ph.D.Person
  • David J. BorgesPerson
  • David W. GhesquierePerson
  • George Mclean Milne Jr., Ph.D.Person
  • Giovanni Caforio, M.D.Person
  • J. Steven Whitaker, M.D., J.D.Person
  • Mariana N. Dimitrova, Ph.D.Person
  • Nadia DacPerson
  • Paul S. WilliamsPerson
  • Peter B. Cancelmo, J.D.Person
  • Sections
    OverviewOMEROS CORP
  • MonitoringOMEROS CORP
  • LeadershipOMEROS CORP
  • BoardOMEROS CORP
  • CommitteesOMEROS CORP
  • Control and votingOMEROS CORP
  • Authority to actOMEROS CORP
  • FinancialsOMEROS CORP
  • GovernanceOMEROS CORP
  • RiskOMEROS CORP
  • AI oversightOMEROS CORP
  • LegalOMEROS CORP
  • CompensationOMEROS CORP
  • Other published claimsOMEROS CORP
  • Coverage gapsOMEROS CORP
  • Linked peopleOMEROS CORP
  • Subject and correctionsOMEROS CORP
  • EvidenceOMEROS CORP
  • Version historyOMEROS CORP
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.